RESMED INC
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
RMD$234.11-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
| PART I – FINANCIAL INFORMATION | Item 1 |
|---|
Condensed Consolidated Statements of Operations (Unaudited)
(In US$ and in thousands, except per share data)
| Three Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenue - Sleep and Breathing Health products | $1,259,802 | $1,169,446 |
| Net revenue - Residential Care Software | 155,012 | 166,136 |
| Net revenue | 1,414,814 | 1,335,582 |
| Cost of sales - Sleep and Breathing Health products | 493,879 | 460,694 |
| Cost of sales - Residential Care Software | 50,368 | 57,224 |
| Total cost of sales | 544,247 | 517,918 |
| Gross profit | 870,567 | 817,664 |
| Operating expenses: | ||
| Research and development | 102,860 | 89,479 |
| Selling, general, and administrative | 314,723 | 281,648 |
| Total operating expenses | 417,583 | 371,127 |
| Income from operations | 452,984 | 446,537 |
| Other income (loss), net: | ||
| Interest income | 21,198 | 15,914 |
| Interest expense | (4,814) | (7,121) |
| Gain (loss) attributable to equity method investments | 1,884 | 1,489 |
| Gain (loss) on equity investments | 5,719 | (6,190) |
| Gain on divestment of subsidiaries | 61,784 | — |
| Other, net | 400 | (3,836) |
| Total other income (loss), net | 86,171 | 256 |
| Income before income taxes | 539,155 | 446,793 |
| Income taxes | 120,742 | 98,257 |
| Net income | $418,413 | $348,536 |
| Basic earnings per share | $2.93 | $2.38 |
| Diluted earnings per share | $2.92 | $2.37 |
| Basic shares outstanding (000's) | 142,989 | 146,182 |
| Diluted shares outstanding (000's) | 143,411 | 146,899 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.